Anacardio

AnaCardio is developing novel drugs to treat heart failure. First in class Ca2+ sensitizing myotrope. AnaCardio has generated proof of concept with peptide X in HFrEF patients and has partnered with Helsinn to license an oral peptide analogue.

AnaCardio joined NOME in 2022 and is headed by Lars Lund MD, Ph.D. and Patrik Strömberg Ph.D., MBA.

Company details

Website

Anacardio.com

More companies

MetsystemNOME2024-04-15T10:43:58+00:00

Metsystem
Metsystem

Digital Health
Droplet IVNOME2024-04-15T08:52:38+00:00

Droplet IV
Droplet IV

Medical Devices
Strike PharmaNOME2024-04-15T08:48:25+00:00

Strike Pharma
Strike Pharma

Therapeutics
InossiaNOME2024-04-15T08:43:52+00:00

Inossia
Inossia

Medical Devices
Linio BiotechNOME2024-04-15T08:37:31+00:00

Linio Biotech
Linio Biotech

Medical Devices
BrainCaptureNOME2024-04-15T08:32:40+00:00

BrainCapture
BrainCapture

Digital Health
2N PharmaNOME2024-04-15T08:22:22+00:00

2N Pharma
2N Pharma

Other, Therapeutics
One-Carbon TherapeuticsNOME2024-04-15T08:21:33+00:00

One-Carbon Therapeutics
One-Carbon Therapeutics

Other, Therapeutics

VIEW ALL PROJECTS

Anacardio

Project Description

Anacardio

Company details

Website

More companies